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Objectives This study compared everolimus-eluting stents (EES) and sirolimus-eluting stents (SES)
for long coronary lesions.
Background Outcomes remain relatively unfavorable for stent-based coronary intervention of le-
sions with long diseased segments.
Methods This randomized, multicenter, prospective trial compared the use of long EES with SES in
450 patients with long (25 mm) native coronary lesions. The primary endpoint of the trial was in-
segment late luminal loss at 9-month angiographic follow-up.
Results The EES and SES groups had similar baseline characteristics. Lesion length was 34.0  15.4
mm in the EES group and 34.3  13.5 mm in the SES group (p  0.85). Nine-month angiographic
follow-up was performed in 80% of the EES group and 81% of the SES group (p  0.69). In-segment
late loss as the primary study endpoint was signiﬁcantly larger in the EES group than in the SES
group (0.17  0.41 mm vs. 0.09  0.30 mm, p for noninferiority  0.96, p for superiority  0.04).
The in-segment binary restenosis rate was also higher in the EES group than in the SES group (7.3%
vs. 2.7%, p  0.046). However, in-stent late loss (0.22  0.43 mm vs. 0.18  0.28 mm, p  0.29) and
in-stent binary restenosis rate (3.9% vs. 2.7%, p  0.53) were similar among the 2 groups. The inci-
dence of any clinical outcomes (death, myocardial infarction, stent thrombosis, target lesion revascu-
larization, and composite outcomes) was not statistically different between the 2 groups.
Conclusions For patients with long native coronary artery disease, EES implantation was associated with
greater angiographic in-segment late loss and higher rates of in-segment restenosis compared with SES im-
plantation. However, clinical outcomes were both excellent and not statistically different. (Percutaneous Treat-
ment of LONG Native Coronary Lesions With Drug-Eluting Stent-III [LONG-DES-III]; NCT01078038) (J Am Coll
Cardiol Intv 2011;4:1096–103) © 2011 by the American College of Cardiology Foundation
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1097The use of drug-eluting stents (DES) has had a major
clinical impact on the treatment of patients with atheroscle-
rotic coronary artery disease. Early generation DES releas-
ing sirolimus or paclitaxel from durable polymers has
reduced angiographic restenosis and the need of repeat
revascularization compared with bare-metal stents (BMS)
(1). Based on the results of pivotal clinical trials, DES has
been widely used for percutaneous coronary intervention
(PCI) in routine clinical practice, including more complex
clinical and anatomic subsets (2). However, restenosis still
occurs, and the incidence of late stent thrombosis is in-
creased with DES compared with BMS, likely as a result of
chronic inflammation and delayed healing of the arterial
wall (3). These adverse events were more pronounced for
“off-label” indications, including higher-risk lesion subsets.
Therefore, newer generation DES have been developed
with the aim to improve upon the efficacy and safety profiles
of early generation devices.
The newer generation everolimus-eluting stent (EES)
consists of a thin-strut, cobalt chromium alloy and releases
everolimus, a semisynthetic sirolimus analogue from an
acrylic and fluoropolymer mixture (4). EES have been
shown to improve clinical and angiographic outcomes com-
pared with early generation paclitaxel-eluting stents (5–8).
To date, however, there are limited data directly comparing
EES with early generation sirolimus-eluting stents (SES),
especially in complex lesion subsets. Despite of markedly
improved efficacy of DES, long coronary lesions still remain at
a higher risk of unfavorable outcomes after PCI, thereby
making differences in the performances of comparative DES
devices more pronounced. This prospective randomized study,
the LONG-DES-III (Percutaneous Treatment of LONG
Native Coronary Lesions With Drug-Eluting Stent-III) trial,
compared angiographic and clinical outcomes of EES and SES
in patients with native long coronary lesions.
Methods
Study design and population. The LONG-DES III trial is
prospective, randomized, single-blind, controlled study
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Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularizationanuscript received May 13, 2011; accepted May 31, 2011.
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1098to treatment with EES (PROMUS, Boston Scientific,
Natick, Massachusetts, or XIENCE V, Abbott Vascular,
Santa Clara, California) or SES (Cypher select; Cordis,
Johnson & Johnson) by means of an interactive web
response system. The allocation sequence was computer
generated, stratified according to participating center, and
blocked with block sizes of 6 and 10 varying randomly.
Patients, but not investigators, were unaware of the treat-
ment assignment.
Stent implantation was performed according to standard
techniques. EES were available in diameters of 2.5, 2.75,
3.0, 3.5, and 4.0 mm and in lengths of 8, 12, 15, 18, 23, and
28 mm; SES were available in diameters of 2.5, 2.75, 3.0,
and 3.5 mm and in lengths of 8, 13, 18, 23, 28, and 33 mm.
In patients with multiple lesions that fulfilled the inclusion
and exclusion criteria, the operator determined the hierarchy
of lesions and declared the target lesion for each patient
before the procedure. The same randomly assigned stent
had to be implanted in all lesions in patients requiring
multilesion interventions, except when the assigned stent
could not be inserted, in which case crossover to another
device was allowed. Full lesion coverage was attempted by
implanting 1 or several stents.
Before or during the procedure, all patients received at
least 200 mg of aspirin and a 300- to 600-mg loading dose
of clopidogrel. Heparin was administered throughout the
procedure to maintain an activated clotting time of 250 s or
longer. Administration of glycoprotein IIb/IIIa inhibitors
was at the discretion of the operator. After the procedure, all
patients received 100 mg/day of aspirin indefinitely, as well
as 75 mg/day clopidogrel for at least 12 months. Use of the
standard post-intervention care was recommended (9).
Study endpoints and deﬁnitions. The primary endpoint was
in-segment late luminal loss at 9 months after the index
procedure (defined as the difference in the minimal luminal
diameter assessed immediately after the procedure and at
angiographic follow-up, measured within the margins, 5
mm proximal and 5 mm distal to the stent). Secondary
angiographic end points were in-stent and segment binary
restenosis and in-stent late loss at 9 months. Secondary
clinical endpoints included death, MI, ischemia-driven
target lesion revascularization (TLR), ischemia-driven tar-
get vessel revascularization, stent thrombosis, a composite of
major adverse cardiac events (MACE) (i.e., death, MI, and
target vessel revascularization) within 12 months, and device
success.
All deaths were considered to have been from cardiac
causes unless a noncardiac cause could be identified. A
diagnosis of MI was based on the presence of new Q waves
in at least 2 contiguous leads on an electrocardiogram or an
elevation of creatine kinase-myocardial band fraction or
troponin I concentration 3 times the normal upper limit
in at least 2 blood samples. Revascularization of the target
lesion and vessel was considered ischemia driven if there was fstenosis of at least 50% of the diameter of the treated lesion
or vessel by quantitative coronary analysis at the indepen-
dent core laboratory in the presence of ischemic signs (i.e.,
positive functional tests) or symptoms, or a target vessel (or
lesion) diameter stenosis of 70% or greater with or without
documented ischemia (10). Stent thrombosis was defined as
definite or probable thrombosis by the Academic Research
Consortium definitions (11). Device success was defined as
a final stenosis of 30% of the vessel diameter after
implantation of the assigned stent only.
Patient follow-up and data management. A 12-lead electro-
ardiogram was obtained and levels of creatine kinase and its
yocardial band isoenzyme were assessed before stenting, 8
o 16 h and again 18 to 24 h after the procedure. Clinical
ollow-up visits were scheduled at 30 days, 9 months, and 12
onth and, monitoring of clinical status, rehospitalizations
r recatheterization, cardiac-related medications, and occur-
ence of adverse events was performed. All eligible patients
ere asked to return for an angiographic follow-up at 9
onths after the procedure, or earlier if anginal symptoms
ccurred.
Clinical, angiographic, procedural, and outcome data
ere collected using a dedicated, electronic case report form
y specialized personnel at the clinical data-management
enter who were unaware of treatment assignments. All
utcomes of interest were confirmed by source documenta-
ion collected at each hospital and were centrally adjudicated
y an independent clinical events committee, whose mem-
ers were blinded as to the assigned stent. An independent
ata and safety monitoring board reviewed the data period-
cally to identify potential safety issues, but there were no
ormal stopping rules.
Quantitative coronary angiography. Coronary angiograms
ere digitally recorded at baseline, immediately after the
rocedure, and at follow-up, and were assessed offline in the
ngiographic core laboratory (Asan Medical Center, Seoul,
orea) using an automated edge-detection system (CAAS
, Pie Medical Imaging, Maastricht, the Netherlands) by
xperienced assessors unaware of the allocated stent. All
easurements were performed on cineangiograms recorded
fter the intracoronary administration of nitroglycerin.
tandard qualitative and quantitative analyses and defini-
ions were used for angiographic analysis (12). The refer-
nce diameter was determined by interpolation.
All quantitative angiographic measurements were ob-
ained within the stented segment (in-stent) and over the
ntire segment, including the stent and its 5-mm proximal
nd distal margins (in-segment). Angiographic variables
ncluded absolute lesion length, stent length, reference
essel diameter, minimum lumen diameter, percent diame-
er stenosis, binary restenosis rate, immediate gain, late loss,
nd patterns of recurrent restenosis. Binary restenosis was
efined as percent diameter stenosis of 50% or greater on
ollow-up angiography, and patterns of angiographic reste-
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1099nosis were quantitatively assessed with the Mehran classifi-
cation (13).
Statistical analysis. The primary objective of the study was
o assess whether the angiographic outcome of treatment
ith the EES was not inferior to the outcome of treatment
ith the SES. To calculate study sample size, we assume an
n-segment late luminal loss of 0.24  0.38 mm in SES
ased on the LONG-DES-II trial (14). Calculation of the
tudy sample size was based on a margin of noninferiority
or in-segment late luminal loss of 0.10 mm, which was
qual to 40% of an assumed late luminal loss of SES. Using
n  level of 0.05 and a statistical power of 80%, we
stimated that 180 patients per group were needed to
emonstrate noninferiority of the EES. Expecting that
pproximately 20% patient would not receive follow-up
ngiography, a total of 450 patients (225 patients per group)
as needed to fulfill the primary endpoint. Sample size was
alculated using PASS software (NCSS, Kaysville, Utah).
All analyses were based on the intention-to-treat princi-
le. Differences between treatment groups were evaluated
y Student t test for continuous variables and by the
hi-square or Fisher exact test for categorical variables.
umulative event curves were generated by means of the
aplan-Meier method. The noninferiority hypothesis was
ssessed statistically with Z-test, by which p values for
oninferiority were calculated to compare differences be-
ween groups with margins of noninferiority, according to
he method of Chow and Liu (15). Trial data were held by
he trial coordination center at the Asan Medical Center.
Table 1. Baseline Clinical Characteristics of the Patients
Characteristics
EES
(n  224)
SES
(n  226) p Value
Age, yrs 62.9 9.9 63.0 9.7 0.98
Male 165 (73.7) 149 (65.9) 0.07
Diabetes mellitus 71 (31.7) 62 (27.4) 0.32
Hypertension 137 (61.2) 128 (56.6) 0.33
Hyperlipidemia 127 (56.7) 128 (56.6) 0.99
Current smoker 52 (23.2) 48 (21.2) 0.61
Previous coronary angioplasty 15 (6.7) 19 (8.4) 0.49
Previous bypass surgery 5 (2.2) 4 (1.8) 0.75
Previous myocardial infarction 10 (4.5) 7 (3.1) 0.45
Left ventricular ejection
fraction, %
60.3 8.1 60.3 7.0 0.93
Multivessel disease 132 (58.9) 118 (52.2) 0.15
Clinical indication 0.13
Silent ischemia 30 (13.4) 26 (11.5)
Chronic stable angina 107 (47.8) 97 (42.9)
Unstable angina 69 (30.8) 92 (40.7)
NSTEMI 18 (8.0) 11 (4.9)
Values are mean SD or n (%). Data are given for the intention-to-treat population.
EES everolimus-eluting stent(s); NSTEMInon–ST-segment elevationmyocardial infarction;
SES sirolimus-eluting stent(s).nalyses were performed using SAS software, version 9.1SAS Institute, Cary, North Carolina) by a statistical analyst
ho was unaware of the type of stent implanted. All p values
re 2-sided, apart from those from noninferiority testing of
he primary endpoint.
esults
Baseline characteristics and procedural results. A total of
50 patients were randomized to receive the EES (n 224)
r the SES (n  226). Table 1 shows the baseline
emographic and clinical characteristics of the study popu-
ation. The lesion and procedural characteristics are shown
n Table 2. Most of clinical, lesion, and procedural charac-
eristics were similar between the 2 groups except the
umber of stents used at the target lesion. The number of
tents implanted in the target lesion was 1.8  0.7, and the
ean total length of the stents was 46.5  17.1 mm. The
ate of device success was 99.1% in both groups.
Angiographic outcomes. Quantitative angiographic results
t baseline, post-procedure, and follow-up are shown in
able 3. Angiographic measurements of lesions before and
fter the procedure were similar in the groups. Follow-up
Table 2. Baseline Lesions and Procedural Characteristics
Characteristics
EES
(n  224)
SES
(n  226) p Value
Lesion characteristics
Target vessel 0.63
Left anterior descending 146 (65.2) 134 (59.3)
Left circumﬂex 27 (12.1) 34 (15.0)
Right coronary 50 (22.3) 57 (25.2)
Ramus intermedius 1 (0.4) 1 (0.4)
TIMI ﬂow grade 0 or 1 14 (6.3) 15 (6.6) 0.87
Bifurcation lesions 94 (42.0) 89 (39.4) 0.58
Thrombus 4 (1.8) 7 (3.1) 0.37
Severe tortuosity 4 (1.8) 3 (1.3) 0.72
Severe calciﬁcation 34 (15.4) 35 (15.5) 0.93
Procedural characteristics
No. of stents used at the target lesion 0.03
1 stent 70 (31.3) 99 (43.8)
2 stents 124 (55.4) 105 (46.5)
3 stents 26 (11.6) 21 (9.3)
4 stents 4 (1.8) 1 (0.4)
Mean 1.8 0.7 1.7 0.7 0.006
Length of stents used at the target
lesion, mm
46.5 16.9 46.4 17.4 0.99
Average stent diameter, mm 3.2 0.4 3.2 0.3 0.15
Maximal pressure, atm 13.8 3.8 15.2 3.9 0.001
Direct stenting 38 (17.0) 39 (17.3) 0.93
Intravascular ultrasound guidance 182 (81.3) 184 (81.4) 0.96
Glycoprotein IIb/IIIa antagonists 5 (2.2) 9 (4.0) 0.29
Values are mean SD or n (%).TIMI Thrombolysis In Myocardial Infarction; other abbreviations as in Table 1.
i
w
d
t
l
P
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 1 0 , 2 0 1 1
O C T O B E R 2 0 1 1 : 1 0 9 6 – 1 0 3
Park et al.
Everolimus- Versus Sirolimus-Eluting Stents
1100angiography was performed in 179 patients (80%) in the
EES group and 184 patients (81%) in the SES group (p 
0.69). The median duration of angiographic follow-up was
274 days (interquartile range: 260 and 299 days) in the EES
group and 275 days (interquartile range: 264 and 297 days)
in the SES group (p  0.82). Patients undergoing angio-
graphic follow-up were younger (p  0.002), less likely to
Table 3. Quantitative Angiographic Analysis
Characteristics EES (n  224) SES (n  226) p Value
Before procedure
Lesion length, mm 34.0 15.4 34.3 13.5 0.85
Reference vessel diameter, mm 3.18 0.47 3.14 0.42 0.34
Minimal luminal diameter, mm 1.07 0.45 1.06 0.45 0.92
Diameter stenosis, % 66.3 13.5 66.1 13.1 0.85
Immediately after procedure
Minimal luminal diameter, mm
In-segment 2.33 0.46 2.31 0.45 0.65
In-stent 2.64 0.42 2.63 0.40 0.80
Proximal margin 3.23 0.54 3.22 0.53 0.82
Distal margin 2.35 0.47 2.33 0.45 0.66
Diameter stenosis, %
In-segment 17.4 9.3 17.2 9.5 0.84
In-stent 9.7 6.8 9.8 6.4 0.89
Proximal margin 10.1 7.7 10.3 8.4 0.74
Distal margin 16.1 9.4 16.3 9.6 0.81
Acute gain, mm
In-segment 1.27 0.57 1.25 0.53 0.77
In-stent 1.57 0.53 1.56 0.51 0.91
Follow-up at 9 months, % 179 (80) 184 (81) 0.69
Late luminal loss, mm
In segment (primary end point) 0.17 0.41 0.09 0.30 0.042
In stent 0.22 0.42 0.18 0.28 0.29
Proximal margin 0.24 0.52 0.13 0.34 0.02
Distal margin 0.11 0.37 0.04 0.28 0.051
Minimal luminal diameter, mm
In-segment 2.17 0.49 2.26 0.46 0.09
In-stent 2.42 0.52 2.47 0.47 0.31
Proximal margin 3.02 0.66 3.14 0.50 0.047
Distal margin 2.25 0.51 2.32 0.45 0.20
Diameter stenosis, %
In-segment 23.7 15.3 21.4 12.2 0.13
In-stent 17.8 14.6 17.1 12.4 0.65
Proximal margin 16.5 15.1 12.9 9.9 0.01
Distal margin 18.8 12.3 16.9 12.2 0.12
Angiographic restenosis*
In-segment 13 (7.3) 5 (2.7) 0.046
In-stent 7 (3.9) 5 (2.7) 0.53
Proximal margin 6 (3.4) 0 0.01
Distal margin 1 (0.6) 0 0.49
Values aremean SD or n (%). *In 1 case in the EES group, angiographic restenosis was detected
concomitantly in the in-stent area and proximal of the margins.
Abbreviations as in Table 1.have diabetes (p 0.03) and previous PCI (p 0.046), andmore likely to have hyperlipidemia (p  0.001) than those
who did not return for angiographic follow-up.
As a primary study endpoint, the mean difference in
in-segment late luminal loss between the EES group and
the SES group was 0.08 mm (95% confidence interval, 0.02
to 0.14), a result failing to show the noninferiority of the
EES (p for noninferiority  0.96) and instead demonstrat-
ing the statistical superiority of the SES (p for superiority
0.042) (Fig. 1, Table 3). The rates of in-segment binary
restenosis were 7.3% in the EES group and 2.7% in the SES
group (p  0.046). However, in-stent late luminal loss
(0.22  0.42 mm vs. 0.18  0.28 mm, p  0.29) and
n-stent binary restenosis rate (3.9% vs. 2.7%, p  0.53)
ere similar between the EES and the SES groups. The
ifference in in-segment luminal changes over time between
he 2 stents was mainly the result of the larger late luminal
oss in the proximal margin of EES than of SES (Table 3).
atterns of in-stent restenosis are shown in Table 4. When
Figure 1. Cumulative Rates of In-Segment Late Luminal Loss at
Follow-Up Angiography
Late luminal loss was deﬁned as the difference between the minimal lumi-
nal diameter at the end of the procedure and the minimal luminal diame-
ter at follow-up.
Table 4. Angiographic Pattern of Restenosis
Characteristics EES (n  13) SES (n  5) p Value
Focal 12 (92.3) 4 (80.0) 0.49
IA (gap) 0 0 NA
IB (margin) 7 (53.8) 0 0.10
IC (focal body) 5 (38.5) 4 (80.0) 0.29
ID (multifocal) 0 0 NA
Diffuse 1 (7.7) 1 (20.0) 0.49
II (intrastent) 0 1 (20.0) 0.28
III (proliferative) 0 0 NA
IV (total occlusion) 1 (7.7) 0 0.99
Values are n (%). Restenosis is classified using the Mehran criteria (13).NA not available; other abbreviations as in Table 1.
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1101we compared the primary endpoint in patients with a single
long stent for the target lesion, the overall finding was also
consistent (0.15  0.43 mm in the EES group vs. 0.04 
0.28 mm in the SES group, p  0.10).
Clinical outcomes. Major clinical events during follow-up
are shown in Table 5. At 1 month, the incidence of clinical
events was similar between the 2 groups. All patients
completed the 12-month clinical follow-up. At 12 months,
the incidence of individual and composite clinical outcomes
did not differ significantly between the 2 groups. The overall
12-month cumulative rate of MACE was similar between
the EES group and the SES group (Fig. 2). During 12
months, there were only 1 case of stent thrombosis (2 days
after the procedure) after use of the EES and no case after
use of the SES.
Discussion
This randomized trial was designed to compare the efficacy
of the newer generation EES with early generation SES for
Table 5. Clinical Events at Follow-Up
Clinical Outcomes
EES
(n  224)
SES
(n  226)
p
Value
Follow-up at 1 month
Death 0 0 NA
Cardiac 0 0 NA
Noncardiac 0 0 NA
Myocardial infarction 21 (9.4) 17 (7.5) 0.48
Q-wave 0 0 NA
Non–Q-wave 21 (9.4) 17 (7.5) 0.48
Death or myocardial infarction 21 (9.4) 17 (7.5) 0.48
Stent thrombosis 1 (0.4) 0 0.50
Target lesion revascularization 1 (0.4) 0 0.50
Target vessel revascularization 1 (0.4) 0 0.50
Follow-up at 12 months
Death 1 (0.4) 0 0.50
Cardiac 0 0 NA
Noncardiac 1 (0.4) 0 0.50
Myocardial infarction 22 (9.8) 18 (8.0) 0.49
Q-wave 0 0 NA
Non–Q-wave 22 (9.8) 18 (8.0) 0.49
Death or myocardial infarction 23 (10.3) 18 (8.0) 0.40
Stent thrombosis 1 (0.4) 0 0.50
Target lesion revascularization 7 (3.1) 5 (2.2) 0.55
Target vessel revascularization 9 (4.0) 6 (2.7) 0.42
Major adverse cardiac events* 32 (14.3) 23 (10.2) 0.18
Target lesion failure, deﬁned post-hoc† 29 (12.9) 22 (9.7) 0.28
Values are n (%). Percentages are from the intention-to-treat analysis. p values were calculated
using the chi-square test or Fisher’s exact test, as appropriate. *The pre-specified major adverse
cardiac events were defined as a composite of all-cause death, myocardial infarction, and
ischemia-driven target vessel revascularization. †Target lesion failure, defined post-hoc, was a
composite of death from cardiac causes, any myocardial infarction (not clearly attributable to a
nontarget vessel), or ischemia-driven target lesion revascularization.Abbreviations as in Tables 1 and 4.very complex coronary lesions with a long diseased segment.
We found that EES implantation was associated with a
greater degree of in-segment late luminal loss as well as an
increased risk of angiographic in-segment restenosis than
was SES implantation. This difference was related to a
relatively larger late lumen loss in the proximal margin with
the EES than with the SES, with no significant difference
in in-stent angiographic parameters. However, clinical out-
comes were both excellent and not statistically different,
suggesting that both stents appear to be very effective in
long coronary lesions with a modest beneficial effect at the
proximal margin in SES.
Despite the improved efficacy of newer DES devices, a
long diseased segment continued to be a major determinant
of worse prognostic outcome in terms of restenosis (16).
Therefore, an investigation to identify differential outcomes
between first and newer generation stents in the treatment
of long coronary lesions is clinically important to the
physician’s choice of devices in these common PCI situa-
tions. As a surrogate marker of DES efficacy, we chose
in-segment late luminal loss at follow-up angiography as the
primary endpoint of this trial because it reflects the overall
degree of neointimal hyperplasia, the primary cause of
restenosis after stent implantation. Although in-stent late
loss may be a useful measure of the pure biological potency
of DES and a more reliable predictor of restenosis (17),
in-segment late loss is the most sensitive measure of the
antiproliferative effectiveness of DES and additionally ac-
counts for the magnitude of lumen renarrowing that occurs
at the margins of the stent, which may reflect stent–balloon
mismatch, geographic miss, drug diffusion effects, and so
on. Because isolated stenoses at stent edges represent an
Figure 2. Kaplan-Meier 12-Month Actuarial Incidence of MACE
Major adverse cardiac events (MACE) were deﬁned as a composite of
death, myocardial infarction, or ischemia-driven target vessel
revascularization.increasingly greater proportion of TLR events with DES
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1102than with BMS, in-segment measures might be a wise
choice as a clinical event surrogate (18). However, it should
be stressed that late luminal loss constitutes only a surrogate
for clinical endpoints. The limitations of surrogate end-
points have been well described, and our results should
therefore be interpreted in this context.
An important issue in our study that requires comment is
that a significant discrepancy between in-segment and
in-stent late luminal loss exists in stent group comparisons.
This phenomenon was mainly attributed to a relatively
pronounced neointimal proliferation in the proximal-edge
portion observed with EES. This finding differs from the
results of most previous stenting trials comparing EES and
other DES comparator (5,6). Although the exact mecha-
nism underlying our findings remains unclear, mechanical
factors related to the procedures (e.g., residual stenosis or
undercoverage of injured segment at the stent margins)
presumably might have contributed to this phenomenon,
given that an effect similarly mitigated within the stent by
the antiproliferative properties of EES and SES resulted in
a similar degree of in-stent angiographic parameters. The
difference in available longest stent length per se (28 mm in
EES and 33 mm in SES) during the study period may also
account, at least in part, for differences in the degree of full
coverage of diseased segments. There could be the possibil-
ity that an appropriate-length stent, sufficient to cover
approximately 3 mm of nondiseased tissue on either side of
the lesion, might be limited with the use of EES, especially
in cases with long coronary lesions of approximately 25- to
28-mm length treated with a single long stent.
Theoretically, the reduced strut thickness (81 m vs. 140
m) and a thinner polymer coating (7.6 m vs. 12.6 m) in
onjunction with improved biocompatibility of the polymer
f the EES may favorably affect neointimal hyperplasia.
owever, this approximation was not compatible with our
bserved findings. Recently, the relative efficacy of EES
ersus SES has been reported in randomized trials. ISAR–
EST-4 (Intracoronary Stenting and Angiographic Re-
ults: Test Efficacy of 3 Limus-Eluting Stents-4) trial
uggested that in-stent late loss is nonsignificantly lower in
ES versus SES (0.23 0.52 mm vs. 0.28 0.57 mm, p
.08) (19). By contrast, a randomized trial comparing EES
nd SES in a broader range of lesion complexity showed
hat in-segment late loss, as a primary endpoint, was
ignificantly larger in the EES group than in the SES
0.10  0.36 mm vs. 0.05  0.34 mm, p  0.05), a finding
onsistent with our study (20). However, a large-scale
andomized clinical study (SORT-OUT IV [Danish Or-
anisation for Randomised Trials with Clinical Outcome]),
ncluding more than 2,600 patients across a wide range of
atient and lesion complexity, demonstrated a similar rate of
he composite endpoint of MACE between the EES group
nd the SES group (4.9% vs. 5.2%) (21).Study limitations. First, our study is an angiographic out-
omes study not powered for clinical outcomes. Therefore,
arger clinical outcome studies are required to detect signif-
cant difference in clinical endpoints. Second, the current
tudy findings cannot be directly extrapolated to a patient
opulation with a more favorable and low-risk profile.
nother limitation of our study was the relatively short
ollow-up period of 12 months. Durable polymers of early
eneration DES have been associated with chronic inflam-
ation of the arterial wall with the potential for delayed
estenosis. Furthermore, previous studies comparing EES
ith paclitaxel-eluding stents, which has been regarded to
ave a similar safety with SES, also reported benefits in
erms of stent thrombosis and MI (8). Therefore, longer-
erm comparison of newer and early generation DES might
e needed to confirm the long-term durability of newer
evices.
onclusions
Both EES and SES appear to be clinically very effective in
long coronary lesions with a modest, but statistically signif-
icant, beneficial effect at the proximal margin in SES.
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